In summary, the Hematology and Oncology franchise had an excellent first quarter in 2018. We are very pleased with our sales performance with strong volume growth, across brands and regions. We have many upcoming catalysts with near term phase III data readouts for Revlimid in lymphoma, Luspatercept in low-risk MDS and beta-thalassemia, as well as Abraxane in Adjuvant pancreatic cancer.